Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4169-4181

  Zhao, Yi Qing ^a   Wang, Li Ping ^a   Ma, Chao ^a   Zhao, Kun ^a   Liu, Ying ^a   Feng, Nian Ping ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Enhanced liposolubility; Lipid nanocapsules; Oral bioavailability; Phospholipid complex; Tetrandrine

Indexed keywords

DISULFIRAM; LIPID NANOCAPSULE; MANNITOL; NANOCAPSULE; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROMETRY; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOANALYSIS; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SUSTAINED DRUG RELEASE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ENHANCED LIPOSOLUBILITY; LIPID NANOCAPSULES; ORAL BIOAVAILABILITY; PHOSPHOLIPID COMPLEX; TETRANDRINE;

ADMINISTRATION, ORAL; ANIMALS; BENZYLISOQUINOLINES; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; MALE; NANOCAPSULES; PARTICLE SIZE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84887349156     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S50557     Document Type: Article

References (40)

1. Cai XH, Wang S, Chen BA. Research advances on the pharmacological effects of tetrandrine. Chin J Nat Med. 2011;6:473-480.
2. Wu JM, Chen Y, Chen JC, Lin TY, Tseng SH. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett. 2010;287(2):187-195.
3. Chen B, Yin L, Cheng J, et al. Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells. Hematology. 2011;16(1):24-30.
4. Cai XH, Wang S, Chen BA. Research advances on the pharmacological effects of tetrandrine. Chin J Nat Med. 2011;9(6):473-480.
5. Takemura H, Imoto K, Ohshika H, Kwan CY. Tetrandrine as a calcium antagonist. Clin Exp Pharmacol Physiol. 1996;23(8):751-753.
6. Tian X, Zhu JB, Wang JS, Li TF. Preparation of tetrandrine lipid emulsion and its therapeutic effect on bleomycin-induced pulmonary fibrosis in rats. Journal of China Pharmaceutical University. 2005;36(3):225-229.
7. Li S, Ji Z, Zou M, Nie X, Shi Y, Cheng G. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine. AAPS PharmSciTech. 2011;12(3):1011-1018.
8. Chen HW, Wang YL, You GY, Chen ZP. Study on pharmacokinetics of tetrandrine liposomes in rats. Journal of Nanjing TCM University. 2010;26(5):353-355.
9. Zeng XM, Martin GP, Marriott C. Tetrandrine delivery to the lung: The optimisation of albumin microsphere preparation by central composite design. Intl J Pharm. 1994;109(2):135-145.
10. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov Today. 2012;9(2):e87-e95.
11. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73(1):1-15.
12. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379(2):201-209.
13. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875-880.
14. Hureaux J, Lagarce F, Gagnadoux F, et al. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm. 2009;73(2):239-246.
15. Sánchez-Moreno P, Ortega-Vinuesa JL, Martín-Rodríguez A, Boulaiz H, Marchal-Corrales JA, Peula-García JM. Characterization of different functionalized lipidic nanocapsules as potential drug carriers. Int J Mol Sci. 2012;13(2):2405-2424.
16. Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res. 2006;23(6):1243-1250.
17. Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux JC. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res. 2006;23(4):752-758.
18. Liu Y, Pan J, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm. 2010;395(1-2):243-250.
19. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013;170(1):15-40.
20. Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21-22):958-965.
21. Peng Q, Zhang ZR, Sun X, Zuo J, Zhao D, Gong T. Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability. Mol Pharm. 2010;7(2):565-575.
22. Yue PF, Yuan HL, Li XY, Yang M, Zhu WF. Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex. Int J Pharm. 2010;387(1-2):139-146.
23. Wu J, Chen D, Zhang R. Study on the bioavailability of baicalin-phospholipid complex by using HPLC. Biomed Chromatogr. 1999; 13(7):493-495.
24. Xia HJ, Zhang ZH, Jin X, Hu Q, Chen XY, Jia XB. A novel drug-phospholipid complex enriched with micelles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine. 2013;8:545-554.
25. Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release. 2006;114(2):242-250.
26. Ruan J, Liu J, Zhu D, et al. Preparation and evaluation of self-nanoemulsified drug delivery systems (SNEDDSs) of matrine based on drug-phospholipid complex technique. Int J Pharm. 2010;386(1-2): 282-290.
27. Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials. 2012;33(5):1583-1588.
28. Liu Y, Wang P, Sun C, et al. Wheat germ agglutinin-grafted lipid nanoparticles: preparation and in vitro evaluation of the association with Caco-2monolayers. Int J Pharm. 2010;397(1-2):155-163.
29. Semalty A, Semalty M, Singh D, Rawat MSM. Preparation and characterization of phospholipid complexes of naringenin for effective drug delivery. J Incl Phenom Macrocycl Chem. 2010;67(3-4):253-260.
30. Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev. 2007;59(6):379-402.
31. Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res. 2010;27(8):1469-1486.
32. Tan Q, Liu S, Chen X, et al. Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech. 2012;13(2):534-547.
33. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1-2):155-163.
34. Gil EC, Colarte AI, Bataille B, Pedraz JL, Rodríguez F, Heinämäki J. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm. 2006;317(1):32-39.
35. Lamprecht A, Bouligand Y, Benoit JP. New lipid nanocapsules exhibit sustained release properties for amiodarone. J Control Release. 2002;84(1-2):59-68.
36. Lamprecht A, Saumet JL, Roux J, Benoit JP. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm. 2004;278(2):407-414.
37. Cheng X, Liu R, He Y. A simple method for the preparation of monodisperse protein-loaded microspheres with high encapsulation efficiencies. Eur J Pharm Biopharm. 2010;76(3):336-341.
38. Varshosaz J, Eskandari S, Kennedy R, Tabbakhian M, Minaiyan M. Factors affecting the production of nanostructure lipid carriers of valproic acid. J Biomed Nanotechnol. 2013;9(2):202-212.
39. Cai X, Luan Y, Jiang Y, et al. Huperzine A-phospholipid complex-loaded biodegradable thermosensitive polymer gel for controlled drug release. Int J Pharm. 2012;433(1-2):102-111.
40. Li J, Liu P, Liu JP, et al. Bioavailability and foam cells permeability enhancement of Salvianolic acid B pellets based on drug-phospholipids complex technique. Eur J Pharm Biopharm. 2013;83(1):76-86.